Jing Watnick

Dr. Jing Watnick is a co-founder of Vigeo and leads the company as its President and Chief Executive Officer. She has more than 20 years of experience in the pharmaceutical industry, including roles in program and portfolio management, strategic planning, business development, alliance management, and preclinical and clinical research. Prior to the launch of Vigeo in 2015, Dr. Watnick was a program lead at Tesaro, Inc., where she directed the Niraparib program through Phase 3 registration trials in ovarian and breast cancer. She also served as a program and portfolio leader at Alexion Pharmaceuticals. Prior to Alexion, Dr. Watnick led global program teams at Novartis Oncology.